RE:RE:Transcript of Dr. Jewett's AGM Presentation - June 2018Considering the low kitty, that they are also presenting papers on the GBM indication (Ruvacare + Warbug effect on RG2 cells), it's almost a signal that they have a jv deal for the GBM indication. Especially considering the latest PR posting and a senior financial position.
So a R/S doesn't make sense considering these hints/events.
A NASDAQ uplisting would make more sense around the publication of 3-month interim data of the first cohort treated @UHN. Ph. 2b data would add to Ph. 1b p#5 and p#6 data.
The reason I say 3-month interim data will be published is that:
- 3-month is a first endpoint required by the new FDA guidelines and it is associated to a complete response (CR). Dr. Kamat contributed to these new guidelines.
- SESEN also published data at this 3-month milestone
Sesen Bio Shares Plunge Despite Reporting Positive 3-month Interim Phase III Results May 22, 2018 Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial. On Monday Cambridge, Mass.-based Sesen said its antibody-drug conjugate (ADC) therapeutic Vicinium was able to help patients achieve a 42 percent complete response rate at three months. Patients in the trial had been previously treated with bacillus Calmette-Gurin (BCG) but have relapsed or did not respond to that first-line treatment. The three-month data from the Phase III trial was revealed at the American Urological Association Annual Meeting in San Francisco.